

**Attachment 5**

**510(k) Summary of Safety and Effectiveness  
PT-Multi Calibrator**

DEC 20 2010

**(a) The device name, including both the trade or proprietary name and the common or usual name and the classification name of the device.**

Trade or proprietary name:	PT-Multi Calibrator
Common or usual name:	Calibrators
Classification name:	Multipurpose System for In Vitro Coagulation Studies (21CFR 864.5425)

**(b) The establishment registration number, if applicable, of the owner or operator submitting the premarket notification submission.**

<u>Establishment Registration Numbers:</u>	<u>Site Activity</u>
9610806	<u>Manufacturer:</u> Siemens Healthcare Diagnostics Marburg GmbH Emil-von-Behring Str. 76 35041 Marburg, Germany
2517506	<u>Distributor/Applicant:</u> Siemens Healthcare Diagnostics Inc. Glasgow Site Bldg. 500, M.S. 514 P.O. Box 6101 Newark, Delaware 19714-6101

**(c) The class in which the device has been put under Section 513 of the Act and, if known, its appropriate panel; or, if the owner or operator determines that the device has not been classified under such section, a statement of the determination and the basis for the person's determination that the device is not so classified.**

Class:	II
Panel:	Hematology
Product Code:	GGN

**(d) Action taken by the person required to register to comply with the requirements of the Act under Section 514 for performance standards.**

To date, no performance standards have been finalized for this device.

**(e) Device Description**

PT-Multi Calibrator is a set of certified plasmas for local PT/INR calibration and/or local verification of the INR system for plasma based procedures using Siemens Dade® Innovin® or Thromborel® S reagents on Siemens BCS® Coagulation Systems.

The calibrator levels are manufactured using a combination of normal and depleted human plasma.

**(f) Device Intended Use**

PT-Multi Calibrator is intended as a calibrator set for local PT/INR calibration and/or local verification of the INR system for plasma based procedures with designated Siemens thromboplastins Dade® Innovin® or Thromborel® S on the BCS® / BCS® XP Systems.

**(g) A statement indicating the device is similar to and/or different from other products of comparable type in commercial distribution, accompanied by data to support the statement. This information may include an identification of similar products, materials, design considerations, energy expected to be used or delivered by the device, and a description of the operational principles of the device.**

The PT-Multi Calibrator is substantially equivalent in intended use to HemosIL INR Validate®, HemosIL®-ISI Calibrate, ISI web Software (K090563), Instrumentation Laboratories Co., Lexington, MA 02421. Both devices are intended as calibrators for monitoring the accuracy and control of oral anticoagulant therapy.

**(e) Suitability of this Device is supported by the data provided below**

Method Comparison studies were conducted at three different sites using at least two lots of PT-Multi Calibrator and the conventional local ISI/MNPT. Precision was evaluated at three different sites with at least two lots of PT-Multi Calibrator. Results of the studies are summarized in the tables below.

BCS System								
	Local Test System ISI / MNPT	MNPT	ISI	PT Multi Calibrator (lot #) Local INR Calibration	without extrapolation		with extrapolation (factor 1.2)	
					n	Regression Analysis	n	Regression Analysis
Denver	Thromborel S lot 545197	10,9	1,12	37591	138	$y=0.95x-0.00$	139	$y=0.95x-0.00$
				37592	136	$y=0.92x+0.06$	139	$y=0.92x+0.06$
	Innovin lot 536999	8,4	0,92	37591	136	$y=0.97x-0.10$	N/A	N/A
				37592	130	$y=0.97x-0.03$	N/A	N/A
Munich	Thromborel S lot 545116	11,5	1,12	37591	118	$y=0.97x-0.02$	123	$y=0.97x-0.02$
				37592	118	$y=0.93x+0.06$	123	$y=0.93x+0.05$
	Innovin lot 536997	8,7	0,92	37591	106	$y=1.10x-0.20$	N/A	N/A
				37592	102	$y=1.09x-0.13$	N/A	N/A
Marburg	Thromborel S lot 545248	12,2	1,05	37591	118	$y=0.92x+0.05$	122	$y=0.92x+0.05$
				38585	110	$y=1.02x+0.01$	121	$y=1.03x+0.00$
	Innovin lot 539128	8,4	0,93	37591	112	$y=0.94x-0.02$	N/A	N/A
				38585	107	$y=0.98x-0.02$	N/A	N/A
all sites	Thromborel S			37591, 37592, 38585	738	$y=0.93x+0.03$	788	$y=0.94x+0.03$
				37591, 37592, 38585	693	$y=0.97x-0.04$	N/A	N/A

20 Day ANOVA Precision Studies on the BCS System

Denver	Local Test System										PT Multi Calibrator lot 07594										PT Multi Calibrator lot 07592									
	Innovin lot 536999					Thromborel S lot 545197					Innovin lot 536999					Thromborel S lot 545197					Innovin lot 536999					Thromborel S lot 545197				
	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP		
Mean (INR)	2.1	3.0	1.0	4.0	2.4	3.7	1.0	3.6	2.0	2.9	3.8	2.4	3.6	1.0	3.6	2.2	2.9	3.8	2.3	3.6	1.0	3.5	2.1	3.0	1.0	3.5	2.1			
Repeatability %	1.7	1.1	1.2	0.8	3.7	1.3	1.2	0.9	1.8	1.2	0.8	3.7	1.3	1.2	0.9	1.8	1.1	1.2	0.8	3.6	1.3	1.0	0.9	1.7	1.1	1.2	0.9			
Within-day-CV %	1.7	1.5	1.2	1.5	3.7	1.6	1.7	1.5	1.8	1.5	1.5	3.7	1.6	1.6	1.5	1.8	1.5	1.5	3.6	1.5	1.5	1.5	1.7	1.5	1.5	1.5	1.5			
Between-run-CV %	10.0	0.9	0.0	1.3	0.5	0.9	1.2	1.1	10.0	0.8	1.3	0.5	0.9	1.0	1.2	10.0	0.9	1.3	0.5	0.9	1.1	1.1	10.0	0.9	1.3	0.5	0.9			
Between-day CV %	0.5	0.7	0.0	0.7	1.5	0.3	0.6	0.0	0.5	0.7	0.7	1.5	0.3	0.6	0.0	0.5	0.7	0.7	1.4	0.4	0.4	0.5	0.5	0.7	0.7	0.5	0.5			
Within-device-CV %	1.8	1.6	1.2	1.6	4.0	1.6	1.8	1.5	1.9	1.7	1.5	4.0	1.6	1.7	1.5	1.9	1.6	1.5	3.9	1.6	1.6	1.6	1.8	1.6	1.6	1.6	1.6			

Munich	Local Test System										PT Multi Calibrator lot 07594										PT Multi Calibrator lot 07592									
	Innovin lot 536997					Thromborel S lot 545116					Innovin lot 536997					Thromborel S lot 545116					Innovin lot 536997					Thromborel S lot 545116				
	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP		
Mean (INR)	2.1	2.8	1.0	3.4	2.5	3.7	1.1	3.4	2.2	2.9	3.6	2.4	3.5	1.0	3.3	2.2	2.9	3.6	2.4	3.5	1.0	3.2	2.1	2.8	1.0	3.2	2.1			
Repeatability %	1.8	1.0	1.0	0.5	3.7	0.6	0.9	0.6	1.3	0.6	0.5	3.7	0.6	1.1	0.6	1.3	1.0	0.5	3.6	0.6	1.0	0.6	1.8	1.0	1.0	0.6	0.6			
Within-day-CV %	1.8	1.0	1.0	0.8	5.0	4.1	1.4	3.0	1.9	0.7	0.8	4.1	5.0	4.1	1.5	3.0	1.9	0.7	4.0	4.9	4.0	4.5	1.8	1.0	1.0	0.8	0.8			
Between-run-CV %	1.3	10.5	10.6	10.6	3.3	4.0	1.1	3.0	1.4	10.5	10.6	3.3	4.1	1.1	3.0	1.4	10.4	10.6	10.6	3.3	3.9	1.1	1.2	1.3	10.5	10.6	10.6			
Between-day CV %	10.0	0.8	1.1	1.1	0.0	0.0	1.5	2.3	10.0	0.9	1.2	1.9	0.0	0.0	1.5	2.3	10.0	0.9	1.2	1.9	0.0	0.0	1.3	10.0	0.8	1.1	1.1			
Within-device-CV %	1.8	1.1	1.3	2.0	5.0	4.1	2.1	3.6	1.9	1.2	1.5	4.1	5.0	4.1	2.2	3.8	1.9	1.1	2.1	4.9	4.0	2.0	1.8	1.1	1.3	2.0	2.0			

Marburg	Local Test System										PT Multi Calibrator lot 07594										PT Multi Calibrator lot 07592									
	Innovin lot 539126					Thromborel S lot 545248					Innovin lot 539126					Thromborel S lot 545248					Innovin lot 539126					Thromborel S lot 545248				
	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP	CPP	C2	NPP	PPP		
Mean (INR)	2.2	3.0	1.0	3.8	2.7	3.8	1.0	3.3	2.4	2.8	3.6	2.5	3.5	1.0	3.1	2.2	3.0	3.7	2.7	3.9	1.0	3.3	2.2	3.0	3.7	2.7	3.3			
Repeatability %	1.3	0.8	1.0	0.4	4.7	0.5	0.9	0.7	1.3	0.7	0.4	4.7	0.5	1.0	0.6	1.3	0.7	0.7	4.4	4.7	0.5	0.9	1.3	0.7	0.7	0.7	0.7			
Within-day-CV %	1.4	0.9	0.7	0.9	4.8	1.4	1.0	1.3	1.4	0.9	0.9	4.8	1.4	1.0	1.3	1.4	1.0	0.7	4.8	1.4	1.0	1.3	1.4	0.9	0.9	0.9	0.9			
Between-run-CV %	10.4	10.7	10.0	10.8	1.0	1.3	0.5	1.1	10.5	10.7	10.2	10.8	1.0	1.3	1.1	10.5	10.7	10.0	10.8	1.1	1.3	1.0	10.4	10.7	10.0	10.8	10.8			
Between-day CV %	10.9	1.3	0.8	1.1	2.3	2.2	0.9	0.3	1.2	1.3	0.8	1.1	2.3	2.2	1.0	10.3	1.3	0.8	1.1	2.3	2.2	1.0	10.9	1.3	0.8	1.1	1.1			
Within-device-CV %	1.6	1.6	0.9	1.4	5.4	2.7	1.4	1.3	1.6	1.6	0.9	1.4	5.3	2.6	1.4	1.3	1.6	1.6	5.4	2.7	1.4	1.3	1.6	1.6	0.9	1.4	1.4			

Sample legend:

CPP	Control Plasma P
C2	CI-Trol 2
NPP	normal plasma pool
PPP	pathological plasma pool

.. below lowest calibrator



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Mail Center – WO66-0609  
Silver Spring, MD 20993-0002

Siemens Healthcare Diagnostics Inc.  
c/o Mr. Radames Riesgo  
Regulatory Affairs & Compliance Manager  
Glasgow Business Community (GBC)  
PO Box 6101 MS 514  
Newark, DE 19702

**DEC 20 2010**

Re: k093848

Trade/Device Name: PT-Multi Calibrator  
Regulation Number: 21 CFR §864.5425  
Regulation Name: Multipurpose System for In Vitro Coagulation Studies  
Regulatory Class: Class II  
Product Code: GGN, JIS  
Dated: November 29, 2010  
Received: November 30, 2010

Dear Mr. Riesgo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed


Page 2 – Mr. Radames Riesgo

predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Maria M. Chan".

Maria M. Chan, Ph.D  
Director  
Division of Immunology and Hematology Devices  
Office of *In Vitro* Diagnostic Device Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

**Attachment 4**

**Indications for Use Statement**

**510(k) Number (if known):** k093848

**Device Name:** PT-Multi Calibrator

**DEC 20 2010**

**Indications for Use:**

**Intended Use:** PT-Multi Calibrator is intended as a calibrator set for local PT/INR calibration and/or local verification of the INR system for plasma based procedures with designated Siemens thromboplastins Dade® Innovin® or Thromborel® S on the BCS® / BCS® XP Systems.


Prescription Use ☒  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use ☐  
(21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

  
Division Sign-Off

Page 1 of 1

Office of In Vitro Diagnostic  
Device Evaluation and Safety

510(k) K093848